About this medicine

Daridorexant reduces the brain’s wake-promoting signal. It is intended to improve sleep and daytime functioning in adults with persistent insomnia.

Persistent insomnia is more than an occasional bad night: difficulty sleeping is accompanied by effects on life while awake. The UK indication includes both duration and daytime impairment. A tablet can address sleep symptoms without explaining their cause; assessment still considers mood, breathing during sleep, other medicines and the sleep pattern.

What is this medicine used for?

NICE recommends it only after CBT for insomnia has not worked, or is unavailable or unsuitable, for qualifying chronic insomnia. SMC separately accepts restricted use in NHS Scotland on similar CBT grounds; local prescribing arrangements still apply.

The marketing authorisation and a health-service recommendation answer different questions. The first defines the licensed illness; NICE and SMC also consider where treatment fits and value for the health service. Scotland’s restricted acceptance specifically requires CBT-I to have failed, been unsuitable or been unavailable. This is not permission to treat every short-lived sleep difficulty.

Which warning signs need help?

Report sleep paralysis, hallucinations or worsening depression promptly. Do not drive unless fully alert. Seek emergency help for severe breathing difficulty, collapse or immediate danger. The UK product carries additional monitoring, inviting reporting of suspected adverse effects.

Additional monitoring means that suspected reactions should be reported through the UK Yellow Card system; it is not an FDA boxed-warning designation. Keep the medicine for the person to whom it was prescribed. Combining it with alcohol can worsen balance and coordination.

How do I take it safely?

The recommended adult dose is 50 mg within 30 minutes before bed, with a 50 mg daily maximum. Some circumstances require 25 mg, including moderate liver impairment or moderate CYP3A4 inhibitors. Taking it after a large meal may delay sleep onset.

Use is once nightly, not repeated during the night. The 25 mg strength has a defined role when a lower dose is appropriate; it is not an extra dose to add independently to 50 mg. Product instructions and the prescriber’s plan govern administration.

What side effects should I know about?

Possible effects include headache, dizziness, nausea, tiredness and sleepiness. Sleep paralysis, vivid sleep-transition hallucinations, unusual dreams and sleepwalking are less common recognised effects.

Tell the prescriber about troublesome daytime tiredness, disturbing dreams or sleepwalking. Adverse-effect lists describe possibilities rather than predicting what one person will experience. Severe allergy, serious breathing difficulty or inability to wake needs emergency assessment rather than waiting for a routine appointment.

Who needs extra care with this medicine?

Narcolepsy is a contraindication. Severe liver impairment is not recommended. Breathing problems, psychiatric illness, substance-use history and older age require individual assessment.

A history of substance misuse calls for careful follow-up even though insomnia trials did not show withdrawal suggesting physical dependence. Breathing studies in selected patients do not establish safety in every respiratory disorder. Fall risk and limited evidence in the oldest age groups also matter.

Can it affect my other medicines?

Strong CYP3A4 inhibitors such as clarithromycin or itraconazole are contraindicated; other inhibitors may require a lower dose. Avoid evening grapefruit. Alcohol and other sedatives can worsen impairment.

Interactions can work in both directions: another medicine can change daridorexant exposure, or daridorexant can affect a companion medicine. Digoxin and dabigatran are examples needing a pharmacist’s review. Review prescribed, over-the-counter and herbal products rather than checking sleep medicines alone.

What check-ups will I need?

Assess response within three months and periodically thereafter. NICE recommends stopping if chronic insomnia has not responded adequately. Review daytime function and adverse effects as well as time asleep.

Useful follow-up asks whether sleep initiation, waking during the night and daytime functioning have improved, alongside adverse effects and ongoing need. A sleep diary can inform the conversation; a better number of hours alone is not the entire treatment goal. The label reports clinical data up to twelve months, not a recommendation for indefinite use.

What about pregnancy, breastfeeding and age?

This is an adult treatment. Pregnancy data are limited, and a small amount enters breast milk. Discuss pregnancy planning and infant feeding with the prescriber.

Small amounts in milk do not establish absence of infant sedation. The feeding decision weighs the infant’s needs and the parent’s treatment need. Under-18 use is not established. Older age alone does not require a different labelled dose, but that does not remove vulnerability to falls or interacting medicines.

What if I miss a dose or want to stop?

If the bedtime dose is forgotten, skip it rather than taking it later overnight. The label permits stopping without dose tapering. Discuss recurrence of insomnia and ongoing care with the clinician.

Not requiring a taper in the product information is distinct from saying insomnia can never recur or misuse is impossible. Continued care should revisit the original sleep problem and non-drug treatment. Do not take a daytime catch-up dose.

How does it work?

Daridorexant helps sleep by reducing the action of orexin, a chemical messenger involved in keeping the brain awake. Orexin A and orexin B normally attach to receiving proteins called OX1R and OX2R. Their signals help maintain waking across connected groups of nerve cells.

Daridorexant blocks both receptor types. It is an antagonist: it occupies the receiving site without producing the usual wake-promoting response. Less orexin signaling can make it easier for sleep to occur, while other brain activity and the systems that organise sleep continue.

This differs from medicines that enhance GABA, a messenger that usually restrains nerve-cell activity. The different target does not, by itself, prove better safety or predict a person’s response. Sleep also depends on daily rhythms, the need for sleep and other influences beyond orexin.

How does it affect my body?

Headache and sleepiness can occur. Next-morning driving can be impaired, especially initially: the label advises around nine hours between a dose and driving, and driving only when fully alert.

Sleep benefit and daytime impairment can coexist. Brief inability to move at a sleep–wake transition is called sleep paralysis; vivid perceptions at that time are not automatically a new psychotic disorder. These experiences still merit review. A person who feels better rested should not assume that driving or hazardous work is safe.

How does my body process it?

CYP3A4 performs most of its metabolism. The terminal half-life is about eight hours. Liver impairment and interacting medicines can increase exposure.

Oral concentrations usually peak within one to two hours. Most elimination is as breakdown products, rather than unchanged medicine, through faeces and urine. Half-life describes falling blood concentration, not a guaranteed duration of sedation. A delayed effect after food is not a reason to take a second tablet.

How do treatment options differ?

CBT for insomnia remains the preferred initial treatment when suitable and accessible. A different receptor mechanism does not make daridorexant free of sedation or misuse concerns.

CBT-I addresses sleep-related patterns through a structured psychological treatment; an orexin antagonist changes a biological wake signal. These are different approaches, not interchangeable doses. US articles about other orexin antagonists do not establish UK licensing or availability of those products.

A closer look at the science

Daridorexant blocks both orexin-1 and orexin-2 receptors. It targets this wakefulness system rather than the GABA receptor mechanism used by benzodiazepines and Z-drugs.

The tablets supply daridorexant as its hydrochloride salt, but their labelled milligrams describe daridorexant itself. Receptor activity and salt formulation are different concepts: a chemical drawing cannot establish an individual dose or equivalence to another hypnotic. The medicine’s major metabolites do not contribute substantially to the intended pharmacological effect.

How was this medicine developed?

The checked UK product record lists first authorisation in August 2022. SMC published its restricted NHS Scotland acceptance in April 2024; authorisation and health-service recommendations are separate decisions.

Studies examined both objectively measured sleep and patient-reported daytime effects. Their group averages cannot guarantee benefit for an individual. The Scottish decision in 2024 concerns NHS use in Scotland; it does not replace the separate UK product authorisation or establish identical access pathways in every nation.

Sources and References

  1. Quviviq 25 mg and 50 mg film-coated tablets — patient leaflet, sections 1–4 and 6

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. NICE TA922: daridorexant for treating long-term insomnia — recommendations 1.1–1.2

    Scope: NICE guidance (England-based); applicability and implementation in other UK nations require the relevant national pathway.

  3. SMC2611: daridorexant — public summary of restricted acceptance in NHS Scotland

    Scope: Scotland.

  4. Quviviq 50 mg film-coated tablets — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  5. Zalzo 5 mg orodispersible tablets — SmPC, sections 4.1–4.9, 5.1–5.2 and 7–10

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  6. Quviviq 25 mg film-coated tablets — SmPC, sections 4.1–4.5

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  7. Quviviq 25 mg and 50 mg — current patient leaflet, sections 1–4

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom.

  8. daridorexant: current US prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.3 Pharmacokinetics; 5.1 CNS-Depressant Effects and Daytime Impairment. This does not establish UK product authorisation or prescribing..

  9. Schizophrenia
  10. NIMH: Understanding psychosis

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top